期刊
BIOMARKERS IN MEDICINE
卷 8, 期 6, 页码 893-911出版社
FUTURE MEDICINE LTD
DOI: 10.2217/BMM.14.14
关键词
angiogenesis; antiangiogenic therapy; biomarkers; cancer; low-dose metronomic chemotherapy; maximum tolerated dose chemotherapy; systematic literature analysis; thrombospondin-1; VEGF
资金
- Clinician Scientist Award from Prostate Cancer Canada
- Joseph and Silvana Melara Cancer Research Fund
Low-dose metronomic (LDM) chemotherapy is a beneficial and very well-tolerated form of chemotherapy utilization characterized by the frequent and uninterrupted administration of low doses of conventional chemotherapeutic agents over prolonged periods of time. While patients resistant to standard maximum tolerated dose (MTD) chemotherapy may still benefit from LDM chemotherapy, there is a lack of predictive markers of response to LDM chemotherapy. We searched the MEDLINE, EMBASE, CENTRAL and PubMed databases for correlative studies conducted as part of LDM chemotherapy trials in order to identify the most promising biomarker candidates. Given the antiangiogenic properties of LDM chemotherapy, angiogenesis-related biomarkers were most commonly studied. However, significant correlations between angiogenesis-related biomarkers and study end points were rare and variable, even so far as biomarkers correlating positively with an end point in some studies and negatively with the same end point in other studies. Pursuing biomarkers outside the angiogenesis field may be more promising.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据